Form 4: Syros Pharmaceuticals CFO Sells 137,803 Shares

Syros Pharmaceuticals' Chief Financial Officer, Jason Haas, sold 137,803 shares of common stock at a weighted average price of $0.2103 per share.

Summary

• Jason Haas, the Chief Financial Officer of Syros Pharmaceuticals, sold 137,803 shares of the company's common stock.
• The sale occurred on November 18, 2024.
• The shares were sold at a weighted average price of $0.2103 per share.
• The transactions took place at prices ranging from $0.19 to $0.2295 per share.

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale by an executive. It doesn't inherently indicate positive or negative sentiment, but the market may interpret it based on the context.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company executives.

Comparison to Industry Standards

• SEC Form 4 filings are a standard practice for publicly traded companies in the United States.
• The sale of shares by a CFO is not unusual, but the market may react to the transaction depending on the size and context.

Stakeholder Impact

• The sale of shares by the CFO could potentially impact shareholder confidence, depending on the market's interpretation of the transaction.

Key Dates

Keywords

Syros Pharmaceuticals, Jason Haas, stock sale, insider trading, common stock, CFO